|
|
|
|
The industry is moving from CRAs with medical backgrounds to those with little or no medical training. This shift can result in subpar monitoring, especially since the expertise needed for oncology studies differs significantly from that required for non-oncology studies.
|
|
|
|
|
As organizations become more skillful in training and monitoring CRAs, the latter can be empowered to enjoy greater flexibility and freedom in scheduling and travel while remaining accountable — ensuring remote work options don't compromise data quality or project timelines.
|
|
|
|
|
A site-centric partnership between a biopharma sponsor and a study site thrives when all parties involved, including study monitors/RSMs, principal investigators, patients, and coordinators, understand each trial's potential challenges and unique needs and can face them together.
|
|
|
|
|
Strong relationships between a sponsor’s CRO and its clinical sites are instrumental to study success. Discover how effective site monitors drive open communication, information-sharing, and a mutual understanding of the other party’s challenges conducive to fruitful site relationships.
|
|
|
|
|
|
|
